Paper Details

  1. Home
  2. Paper Details

Exposure-safety and efficacy response relationships and population pharmacokinetics of eslicarbazepine acetate.

Author: Ben-MenachemE, BlumD, CarreñoM, FalcãoA, Fiedler-KellyJ, GidalB E, GrinnellT, JacobsonM P, LudwigE, MoreiraJ, PassarellJ, RochaF, Soares-da-SilvaP, SunkaraneniS

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study developed pharmacokinetic (PK) and pharmacodynamic (PD) models for eslicarbazepine acetate (ESL), a once-daily antiepileptic drug (AED) for focal-onset seizures (FOS). These models aid in dose selection, identify significant AED drug interactions, and quantify relationships between exposure and safety and efficacy outcomes.
Paper Details　
Original Abstract of the Article :
Eslicarbazepine acetate (ESL) is a once-daily (QD) oral antiepileptic drug (AED) for focal-onset seizures (FOS). Pharmacokinetic (PK) and pharmacodynamic (PD) models were developed to assess dose selection, identify significant AED drug interactions, and quantitate relationships between exposure and...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6099471/

データ提供：米国国立医学図書館（NLM）

Eslicarbazepine Acetate: Navigating the Desert of Epilepsy Treatment

Epilepsy is a complex and challenging condition, with a vast desert of treatment options to explore. This research investigates the safety and efficacy of eslicarbazepine acetate (ESL), a once-daily oral antiepileptic drug, for treating focal-onset seizures (FOS). The study develops pharmacokinetic (PK) and pharmacodynamic (PD) models to assess dose selection, identify drug interactions, and explore the relationship between ESL exposure and safety and efficacy outcomes. By examining the complex interplay between ESL and the body, the study seeks to optimize treatment strategies and improve the lives of patients with epilepsy.

Understanding ESL: A New Oasis in Epilepsy Treatment

The study revealed that ESL demonstrates promising safety and efficacy profiles in treating FOS. The PK and PD models developed in the study provide valuable insights into the drug's behavior within the body, guiding dose selection and identifying potential drug interactions. The study's findings suggest that ESL offers a potential new path for effective and safe treatment of FOS, contributing to the vast oasis of epilepsy treatment options.

Finding Relief in the Desert: Effective Epilepsy Treatment

This research provides a crucial roadmap for navigating the challenging desert of epilepsy treatment. The study's findings offer valuable insights into the safety and efficacy of ESL, highlighting its potential as a new and promising treatment option for FOS. By understanding the intricacies of ESL's behavior within the body, we can better tailor treatment strategies and improve the lives of those living with epilepsy.

Dr.Camel's Conclusion

This research offers a refreshing oasis in the desert of epilepsy treatment, highlighting the potential of eslicarbazepine acetate (ESL) as a new and promising treatment option. The study's findings emphasize the importance of personalized care, taking into account individual patient characteristics and the intricate interplay between ESL and the body. As we continue to explore the vast desert of epilepsy treatment, this research offers a valuable compass, guiding us towards more effective and personalized care for those living with this challenging condition.

Date :
  1. Date Completed 2018-11-05
  2. Date Revised 2021-01-09
Further Info :

Pubmed ID

29732549

DOI: Digital Object Identifier

PMC6099471

Related Literature

Article Analysis
・Side Effects of eslicarbazepine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.